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Connexin 43 plays a role in proliferation and migration of
pulmonary arterial fibroblasts in response to hypoxia
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Abstract
Pulmonary hypertension (PH) is a disease associated with vasoconstriction and remodelling of the pulmonary vasculature.
Pulmonary artery fibroblasts (PAFs) play an important role in hypoxic-induced remodelling. Connexin 43 (Cx43) is involved in
cellular communication and regulation of the pulmonary vasculature. Using both in vitro and in vivo models of PH, the aims of this
study were to (i) investigate the role of Cx43 in hypoxic-induced proliferation and migration of rat PAFs (rPAFs) and rat pulmonary
artery smooth muscle cells (rPASMCs) and (ii) determine whether Cx43 expression is dysregulated in the rat sugen5416/hypoxic
model of PH. The role of Cx43 in hypoxic-induced proliferation and migration was investigated using Gap27 (a pharmacological
inhibitor of Cx43) or genetic knockdown of Cx43 using siRNA. Cx43 protein expression was increased by hypoxia in rPAFs but
not rPASMCs. Hypoxic exposure, in the presence of serum, resulted in an increase in proliferation of rPAFs but not rPASMCs.
Hypoxic exposure caused migration of rPAFs but not rPASMCs. Phosphorylation of p38 mitogen-activated protein kinase (MAPK)
and ERK1/2 were increased by hypoxia in rPAFs. The effects of hypoxia on proliferation, migration and MAPK phosphorylation in
rPAFs were attenuated in the presence of Gap27 or Cx43 siRNA. Cx43 protein expression was increased in sugen5416/hypoxic
rat lung; this increased expression was not observed in sugen5416/hypoxic rats treated with the MAPK pathway inhibitor GS-
444217. In conclusion, Cx43 is involved in the proliferation and migration of rPAFs in response to hypoxia via the MAPK
signalling pathway.
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Pulmonary hypertension (PH) is a complex vascular disease
which is characterised by an increase in pulmonary arterial
pressure (PAP) and remodelling of the pulmonary arteries.1
PH develops in response to hypoxia in most species includ-
ing humans,2 and as such hypoxia has been a commonly
used model of PH for decades, both in vitro and in vivo.
Exposure to hypoxia results in an acute increase in PAP
due to hypoxic pulmonary vasoconstriction. This is followed
by pulmonary vascular remodelling leading to sustained
increases in PAP.3 The pulmonary artery is composed of
three main cell types: fibroblasts, smooth muscle and
endothelial cells. Pulmonary artery fibroblasts (PAFs) play
a major role in pulmonary vascular remodelling, particu-
larly in response to hypoxia. They have been shown to pro-
liferate and migrate in response to hypoxia and mediate the
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proliferation and migration of pulmonary artery smooth
muscle cells (PASMCs).2
Connexins and pannexins are transmembrane proteins
known to play an important role in cellular communication.
Oligomerisation of these proteins leads to the formation of
membrane-associated channels that can mediate the release
of small chemical signalling molecules such as adenosine
triphosphate, cyclic adenosine monophosphate and cyclic
guanosine monophosphate or ions such as calcium from
the cell cytosol to the extracellular milieu.4 Connexin chan-
nels from neighbouring cells can align to form a gap junc-
tion allowing transfer of small molecules directly from the
cytoplasm of one cell to that of another.5 Connexins 37
(Cx37), 40 (Cx40), 43 (Cx43), 45 (Cx45) and pannexin-1
(Panx1) are expressed throughout the vascular system, and
their role in regulation of the systemic vasculature is well
documented.6 Interestingly, recent evidence suggests a role
for connexins in regulation of the pulmonary vasculature.
Cx37 and Cx40 expression are downregulated in pulmonary
artery endothelial cells (PAECs) from pulmonary arterial
hypertension (PAH) patients.7 In addition, mice genetically
deficient in Cx40 are protected against hypoxic-induced PH
and hypoxic pulmonary vasoconstriction.8 Cx43 levels are
increased in pulmonary arteries from patients with PH asso-
ciated with hypoxemic chronic lung disease, while Cx43
levels are decreased in pulmonary arteries from patients
with idiopathic PAH. In addition, mice genetically deficient
in Cx43 are partially protected against hypoxic-induced
PH.9 Pharmacological inhibition of Cx43 can reduce pheny-
lephrine-induced contraction of pulmonary arteries derived
from both chronic hypoxic and monocrotaline rats and also
reduce 5-hydroxytryptamine (5-HT)-induced contraction of
pulmonary arteries derived from control rats.10 Mice defi-
cient in Cx43 show reduced pulmonary vascular relaxation,
and pharmacological inhibition of Cx43 also reduces pul-
monary vascular relaxation.11 In addition, Cx43 can med-
iate 5-HT signalling between rat PAECs and rat PASMCs
(rPASMCs).12 Transfer of 5-HT between these cell types
was inhibited by the non-specific gap junction blocker, car-
benoxolone or by siRNA knockdown of Cx43, but not by
the serotonin transporter inhibitor fluoxetine.13 The nitric
oxide synthase inhibitor, asymmetric dimethyl arginine
(ADMA), is upregulated in PAH patients. ADMA has
been shown to inhibit protein expression and membrane
localisation of Cx43 in pulmonary endothelial cells. The
effect of ADMA on reduced gap junctional communication
is prevented by over-expression of Cx43 or by treatment
with rotigaptide, which enhances connexin coupling.14
In HeLa cells transfected to express Cx43, and mouse
systemic vascular smooth muscle cells, Cx43 mediated
proliferation and migration via downstream activation of
p38 mitogen-activated protein kinase (MAPK).15,16 Previous
work from our laboratory has determined that activation of
this pathway plays a crucial role in PAF proliferation in
response to acute hypoxia. For example, phosphorylation of
p38 MAPK is upregulated in PAFs in response to hypoxia,
and inhibition of p38 MAPK attenuates hypoxic-induced pro-
liferation and migration of PAFs.2 It has also been shown that
inhibition of the MAPK pathway leads to decreased prolifera-
tion, migration and p38 MAPK expression in rat PAFs
(rPAFs) and also attenuates the development of PH in
sugen5416/hypoxic rats.17 Apoptosis signal-regulating kinase-
1 (ASK-1) is an upstream regulator of the MAPK pathway. In
response to oxidative stress, ASK-1 undergoes auto-phosphor-
ylation and activation of downstream p38 MAPK.16
Inhibition of ASK-1 leads to decreased proliferation, migra-
tion and p38 MAPK expression in rPAFs and also attenuates
the development of PH in sugen5416/hypoxic rats.16
Until now, investigations of connexin expression and
function in the pulmonary vasculature have focussed on
PAECs and PASMCs. For example, Cx37, Cx40 and
Cx43 are expressed in rat PAECs (rPAECs), while Cx37
and Cx43 are expressed in rPASMCs.18 Functional myo-
endothelial gap junctions were demonstrated by using co-
cultures of rPAECs and rPASMCs.12 However, to the best
of our knowledge, the expression and function of connexins
in PAFs have yet to be investigated. Thus, in this study, we
cultured rPAFs and (for comparison) rPASMCs and exam-
ined gene and/or protein expression of Cx37, Cx40, Cx43,
Cx45 and Panx1. We subsequently determined the effects of
the connexin mimetic peptide Gap27, which is targeted to
the SRPTEKTIFII sequence (amino acids 204–214) on the
second extracellular loop of Cx43 and inhibits both Cx37
and Cx43, on hypoxic-induced proliferation, migration and
activation of MAP kinase pathways in rPAFs.19–21 In addi-
tion to pharmacological inhibition with Gap27, we also
investigated the effects of genetic knockdown of Cx43
using siRNA. As well as performing in vitro experiments
using primary pulmonary vascular cells, we were also inter-
ested in determining if Cx43 expression was dysregulated in
a rodent model of PH. We chose the sugen5416/hypoxic rat
as this model capitulates the vascular lesions observed in
human disease and is thought to be more robust than the
hypoxic rodent model.22 Thus, we investigated Cx43 expres-
sion in whole lung tissue derived from sugen5416/hypoxic
rats, including a subgroup dosed with an ASK-1 inhibitor.
Methods
Materials
All reagents were of Analar grade and were obtained from
Sigma (Poole, Dorset, UK) unless specified otherwise. All
tissue culture flasks and media were obtained from
Invitrogen (Paisley, Renfrewshire, UK). Foetal bovine
serum (FBS) was obtained from Imperial Laboratories
(Andover, Hants, UK). Rabbit polyclonal antibodies specific
for the activated dual phosphorylated forms of the two MAP
kinase family members (ERK1/ERK2) (Thr202/Tyr204) and
p38 MAPK (Thr180/Tyr182) and their appropriate control
antibodies were obtained from Cell Signalling Technology
(Danvers, MA, USA). Rabbit polyclonal antibodies for
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Cx37, Cx40 and Cx43 were obtained from Alpha Diagnostics
(San Antonio, TX, USA), Invitrogen (Paisley, Renfrewshire,
UK) and Sigma (Poole, Dorset, UK), respectively. Secondary
goat anti-rabbit horseradish peroxidase (HRP) antibody was
obtained from New England Biolabs (Ipswich, MA, USA).
Gap27 was purchased from AdooQ (Irvine, CA, USA) and
the Cx43 siRNA from Integrated DNA Technologies
(Skokie, IL, USA).
Animals
All animal procedures were carried out in accordance with
Directive 2010/63/EU of the European Parliament. Ethical
approval was granted from the University of Glasgow
Animal Welfare and Ethical Review Board (P965255C4).
Primary rPAFs and rPASMCs were obtained from adult
male Sprague-Dawley rats (3 months of age) maintained in
normoxic conditions on a 12 h light/dark cycle and
allowed free access to standard diet and water. Rats were
euthanised by exsanguination under terminal anaesthesia
(5% isoflurane supplemented in O2) and heart and lung
tissue dissected free.
Sugen5416/hypoxic rat model of PH
Male Sprague-Dawley rats (4 weeks old) received a subcuta-
neous injection of sugenSU5416 (20mg/kg) prior to 2 weeks
of hypobaric hypoxia (550 mbar) and a subsequent 3-week
normoxic phase. Control rats were dosed with a vehicle
substance (0.5% (w/v) carboxymethylcellulose sodium,
0.9% (w/v) sodium chloride, 0.4% (v/v) polysorbate 80,
0.9% (v/v) benzyl alcohol in deionised water). One group
of rats received the ASK-1 inhibitor GS-444217 administered
in the chow (a maximum of 10mM) during the 3-week nor-
moxic phase. The control groups received standard chow.
Rats were euthanised at the end of the 3-week normoxic
phase by anaesthetic overdose (5% isoflurane supplemented
in O2). Heart and lung tissue were dissected free.
Primary culture of rPAFs and rPASMCs
Main and branch pulmonary artery (diameter 0.5–1.5mm)
was dissected free from freshly excised rat lungs. The section
was then cut longitudinally and opened into a flat sheet. The
fibroblasts were isolated using a modified technique of
Freshney.23 Muscular tissue and endothelial cell layers
were removed by gentle abrasion of the vessel using a
razor blade. The adventitia was dissected into approxi-
mately 1 mm3 portions and evenly distributed over the
base of a 25 cm2 culture flask containing 2ml of
Dulbecco’s modification of Eagle’s medium (DMEM) sup-
plemented with 20% FBS, with penicillin/streptomycin (400
iu/ml and 400 mg/ml) and L-glutamine (2mM) until cellular
outgrowth was observed. We have previously shown by
staining for vimentin that this technique provides a pure
culture of fibroblasts.2
rPASMCswere prepared using a similar technique; however,
the intimal and adventitial layers were not removed by gentle
abrasion as with the rPAF preparation. Staining for a smooth
muscle actin proved a pure culture of smooth muscle cells.
rPAFs and rPASMCs were maintained in DMEM con-
taining 10% FBS, supplemented with penicillin/streptomy-
cin (200 iu/ml and 200 mg/ml) and L-glutamine (27mg/ml)
and used between Passage 3 and 7.
Growth of cells in a hypoxic environment
A humidified temperature controlled incubator (Wolf Galaxy
R, Nottingham, UK) was used as a hypoxic chamber. For
hypoxic experiments, primary cultures of rPAFs or
rPASMCs were quiesced in serum-free media (SFM) for
24h then transferred to hypoxic conditions (5% O2, 5%
CO2 and balance N2) over a 24-h experimental period.
Over the 24-h experimental period, cells were incubated
with SFM or media supplemented with 0.1% or 1% FBS.
We have previously shown that rPAFs proliferate in response
to hypoxia in the presence of 1% FBS but not 0.1% FBS.22
Western blotting
rPAFs and rPASMCs were grown to 90% confluency in 6-
well plates and quiesced for 24h in SFM. The cells were then
stimulated with 1% FBS and placed in either the normoxic or
hypoxic incubator for 24h. Reactions were terminated by the
addition of 50-ml ice-cold radioimmunoprecipitation assay
buffer (50mM Tris (pH 7.4), 150mM sodium chloride, 2%
(v/v) NP 40, 0.25% (w/v) sodium deoxycholate, 1mM EGTA
(ethylene glycol-bis(-aminoethyl ether)-N,N,N’,N’-tetraace-
tic acid), 10mM sodium orthovanadate, 0.5mM phenyl-
methylsulfonyl fluoride, chymostatin (10mg/ml), leupeptin
(10mg/ml), antipain (10mg/ml) and pepstatin A (10mg/
ml)) and kept on ice for 30min to facilitate the extraction
of cellular proteins. The samples were centrifuged at
12,000g for 15min, and the resulting supernatants containing
the solubilised proteins were used for Western blot analysis.
Protein content of the samples was determined by the Micro
BCA Protein Reagent Kit (Pierce, IL, USA). Samples (50mg)
were reduced and electrophoresed on 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis resolving gels
under reducing conditions. The resolved proteins were trans-
ferred to polyvinylidene difluoride (Millipore, Watford, UK)
and blocked at room temperature with 10% (w/v) non-fat
dried milk in phosphate-buffered saline (PBS)/Tween 20 (v/
v 0.1%) under constant agitation. Primary antibody was
incubated with the blot for at least 1 h at room temperature.
The blots were then washed in PBS/Tween before incubating
with goat anti-rabbit IgG HRP in 5% (w/v) non-fat dried
milk for 1 h with constant agitation. For each member of
the MAPK family studied, activation was determined by
reactivity with the antibody to the dually phosphorylated
protein and compared to the control antibody which recog-
nised both the active and inactive forms of the protein (total
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MAPK), and a ratio was calculated. The blots were thor-
oughly washed and then incubated with enhanced chemilu-
minescence (ECL) reagent (Amersham Life Sciences, UK)
and exposed to film. Image J software was used to attribute
densitometry values to quantify the results.
RNA analysis
RNA extraction. rPAFs and rPASMCs were grown to 90%
confluency in 6-well plates and quiesced for 24 h in SFM.
Cells were then stimulated with 1% FBS and placed in either
the normoxic or hypoxic incubator for 24 h. To extract
RNA from rPAFs and rPASMCs, lysis was performed
using QIAzol lysis reagent and extracted with the
miRNEASY extraction kit according to manufacturer’s
instructions. Initially, 700 ml QIAzol was added to the
cells, and they were scraped as previously described. For
RNA extraction, chloroform was added, and tubes were
shaken vigorously for separation of RNA from DNA, pro-
teins and lipids. The RNA was then precipitated with 100%
RNA-free ethanol. The sample was transferred onto a spin
column provided by the manufacturer to undergo spin
column-based nucleic acid purification. Samples were ana-
lysed by a NanoDrop, ND-1000 spectrophotometer
(Thermo Scientific, UK) to determine RNA concentrations.
Reverse transcription. Extracted RNA samples were reverse
transcribed using TaqMan reverse transcription reagents
(Applied Biosystems, CA, USA) as per manufacturers’ instruc-
tions. [AW: RT has been expanded as Reverse Transcriptase
buffer. Kindly confirm that this is correct or edit as needed.]
Approximately 1mg RNA was transcribed per sample in a
cocktail of Reverse Transcriptase buffer, 25mM magnesium
chloride (MgCl2), deoxynucleotide triphosphates, random hex-
amers, RNase inhibitors and Multiscribe. Reverse transcrip-
tion was performed using the Veriti Thermal Cycler (Life
Technologies, Paisley, UK) under the following cycling condi-
tions: 10min at 25C to maximise primer RNA template bind-
ing, 30min at 48C for reverse transcription and 5min at 95C
to deactivate reverse transcription.
Quantitative real-time polymerase chain reaction. Quantitative
real-time polymerase chain reaction (qRT-PCR) was used
to assess mRNA expression. Taqman PCR master mix and
fluorescently tagged Taqman primers (Supplemental
Table 1) (Primer design, Southampton, UK) were used.
Fluorescence was measured using the ViiA7TM real-time
PCR System (Life Technologies, Paisley, UK). The cycle
conditions were 50C for 2min, 95C for 10min and 40
cycles of 95C for 15 s, 60C for 1min.
Cx43 siRNA
siRNA duplex sequences targeted to Cx43
(TriFECTaRNAi Kit from Integrated DNA Technologies,
Tyne and Wear, UK) were used to knockdown Cx43 gene
expression. A scrambled siRNA was used as a control.
siRNA transfection was carried out using Lipofectamine
3000 transfection reagent (Invitrogen, Paisley, UK).
Lipofectamine 3000 was mixed with the siRNAs and incu-
bated for 15min at room temperature allowing complexes to
form. rPAFs were then transfected with a final concentration
of 5 nM siRNA. Proliferation and migration assays were per-
formed 24h post transfection. Transfection of rPAFs with
siRNA targeting Cx43 resulted in approximately 50% reduc-
tion in Cx43 protein expression (Supplemental Fig. 1).
Proliferation assays
To determine proliferation, confluent 75 cm2 flasks of rPAFs
or rPASMCs were split, and 1/12 of the cells were evenly
distributed over 2 24 well plates. Cells were grown in
10% FBS DMEM to 50% to 60% confluency and then
quiesced in SFM for 24h. After being quiesced, 0.1% FBS,
1% FBS or 1% FBS in the presence of Gap27 (300mM) or
Cx43 siRNA (5nM) was added before cells were placed in
normoxia or hypoxia for 24h. 1% FBS was used as it has
previously been shown to promote PAF proliferation in
hypoxia.17,24 We wished to verify that 0.1% FBS did not
cause proliferation of cells in the presence of hypoxia, and
therefore, 0.1% FBS could be used for subsequent migration
assays. Cells were counted using an automated cell counter
(Countess II, Life Technologies, UK). Cell culture media was
aspirated, and cells were washed in 500ml of sterile PBS. After
removing the PBS, 100ml of trypsin (Life Technologies, UK)
was added to each well. The plate was placed at 37C to aid
the detachment of the cells. The detached cells were re-sus-
pended in 700ml of SFM per well and mixed. The suspended
cells were centrifuged at 2600 g for 5min, and the pellet was
then re-suspended in equal volumes of SFM and trypan blue
and loaded onto glass slides and inserted into the Countess II
to determine cell concentration per ml.
Migration assays
Cells were seeded into 6-well plates and left to grow until
100% confluent. Once fully confluent, the cells were quiesced
in SFM for 24h, and an initial scratch was made in each well
and was photographed. After being quiesced, 0.1% FBS or
0.1% FBS in the presence of Gap27 (300mM) or Cx43
siRNA (5nM) was added to the cells for 24h normoxic or
hypoxic exposure. After 24h, the scratch was photographed
for comparison with the previous images. Cell migration was
analysed by measuring the changes in scratch width and con-
verting this into a percentage migration.
Statistics
Data were analysed using a two-way analysis of variance
(ANOVA) followed by either a Tukey post hoc test
or Dunnett’s multiple comparison test as appropriate.
A value of p< 0.05 indicated statistical significance.
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Results
Effects of hypoxia on connexin gene expression in rPAFs
and rPASMCs
The presence of mRNA for GJA4 (encoding Cx37), GJA5
(encoding Cx40), GJA1 (encoding Cx43), GJC1 (encoding
Cx45) and PANX-1 in rPASMCs and rPAFs in SFM
(Fig. 1a and b) and 1% serum conditions (Fig. 1c and d)
was confirmed using qRT-PCR. In both cell types, GJA1
was found to be the most predominant connexin gene
expressed, while GJA5 was expressed only at very low levels.
After 24h of hypoxia, no changes in expression of GJA4,
GJA5, GJA1, GJC1 or PANX-1 were found in rPAFs (Fig.
1a and c) or rPASMCs (Fig. 1b and d). GJA1 expression was
upregulated in rPAFs exposed to 1% serum conditions com-
pared to those in SFM, while there was no change in expres-
sion of GJA4, GJA5, GJC1 or PANX-1 between rPAFs
cultured in SFM or 1% serum (Supplemental Fig. 2). There
was no change in expression of GJA1, GJA4, GJA5, GJC1 or
PANX-1 between rPASMCs cultured in SFM or 1% serum
(Supplemental Fig. 2).
Effects of hypoxia on connexin protein expression in
rPAFs and rPASMCs
Connexin protein expression was examined using Western
blot analysis. We focused on Cx37, Cx40 and Cx43 as they
have previously been shown to have a role in regulation of
the pulmonary vasculature.10,11,15 In rPAFs in both SFM
and 1% FBS, hypoxic exposure increased protein expression
of Cx37 (Fig. 2a) and Cx43 (Fig. 2b) but had no effect on
protein expression of Cx40 (Fig. 2c). In rPASMCs, hypoxic
exposure in the presence of 1% FBS decreased protein
expression of Cx37, with no effect observed in the presence
of SFM (Fig. 2d). In both SFM and 1% FBS, hypoxic
Fig. 1. Expression of connexins in rPAFs (a) and rPASMCs (b) in serum-free media and in rPAFs (c) and rPASMCs (d) in media containing 1%
serum. In both cell types, under serum-free conditions and in the presence of 1% serum, GJA1 was found to be the most predominant connexin
gene expressed, while GJA5 was expressed although at very low levels. In hypoxic conditions, no changes in expression of GJA4, GJA5, GJA1, GJC1
or PANX-1 were found in rPAFs or in rPASMCs. Data expressed as mean SEM, and analysis was carried out by two-way ANOVA with a
Dunnett’s multiple comparison test. *p< 0.05, **p< 0.01, ***p< 0.001, vs. GJA1, n¼ 6.
rPAF: rat pulmonary artery fibroblasts; rPASMC: rat pulmonary artery smooth muscle cells.
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exposure had no effect on protein expression of Cx43
(Fig. 2e) and decreased protein expression of Cx40 (Fig. 2f).
Cx43 inhibition prevents cell proliferation in rPAFs but not
rPASMCs
Hypoxic exposure resulted in increased proliferation of
rPAFs only in the presence of 1% FBS. Hypoxic exposure
did not result in proliferation of rPAFs cultured in SFM or
0.1% FBS (Fig. 3a and b). Proliferation of rPAFs in
response to hypoxia in the presence of 1% FBS was inhib-
ited by Gap27 (Fig. 3a) or Cx43 siRNA (Fig. 3b). rPAFs did
not proliferate when cultured in SFM, 0.1% or 1% FBS
under normoxic conditions, and the addition of Gap27 or
Cx43 siRNA had no further effect (Fig. 3a and b).
rPASMCs proliferated in response to 1% FBS under nor-
moxic conditions. Hypoxia had no further effects on FBS-
induced proliferation in rPASMCs. Gap27 did not inhibit
FBS-induced proliferation of rPASMCs (Fig. 3c). Cell pro-
liferation images are shown in Supplemental Fig. 3.
Cx43 inhibition prevents cell migration in rPAFs but not
rPASMCs
Having established that rPAFs cultured in hypoxic condi-
tions in the presence of 0.1% FBS do not show a prolifera-
tive response (Fig. 3a), we used this serum concentration to
study the effects of hypoxia on cellular migration. Hypoxia
resulted in an increase in rPAF migration, which was inhib-
ited by either Gap27 (Fig. 4a) or Cx43 siRNA (Fig. 4b).
Fig. 2. Protein expression of Cx37, Cx40 and Cx43 in rPAFs and rPASMCs. In rPAFs, hypoxia increased Cx37 (a) and Cx43 (b) protein expression,
while Cx40 expression was unchanged (c). In rPASMCs, hypoxia decreased Cx37 expression under 1% serum conditions (d). Cx43 expression was
unchanged by hypoxia in rPASMCs (e), and decreased Cx40 expression was observed under both serum free and 1% serum conditions (f). Data
expressed as mean SEM, and analysis was carried out by two-way ANOVA with a Tukey post hoc test. *p< 0.05, **p< 0.01, n¼ 4–5.
rPAF: rat pulmonary artery fibroblasts; rPASMC: rat pulmonary artery smooth muscle cells; Cx37: connexin 37; Cx43: connexin 43; Cx40:
connexin 40.
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In rPASMCs, hypoxia did not alter the rate of migration,
and Gap27 had no effects on the rate of migration (Fig. 4c).
Neither rPAFs nor rPASMCs migrated under normoxic
conditions (Supplemental Fig. 4).
Gap27 inhibits phosphorylation of p38 MAPK and ERK
MAP kinase activity in rPAFs exposed to acute hypoxia
Phosphorylation of both p38 MAPK and EE1/2 MAPK has
previously been shown to play a role in hypoxic-induced
proliferation and migration of rPAFs.2 As we have shown
Gap27 to inhibit hypoxic-induced rPAF proliferation and
migration, we investigated if Gap27 altered the phosphory-
lation of p38 MAPK and ERK1/2 MAPK. In the present
study, hypoxia caused an increase in phosphorylation of
both p38 MAPK and ERK1/2 MAPK, both of which
were inhibited in the presence of Gap27 (Fig. 5a and b).
Connexin 43 expression in whole lung tissue from
sugen5416/hypoxic rats treated with an ASK1 inhibitor
To complement the changes observed in connexin expres-
sion in our cellular model of PH, we investigated changes in
Cx43 gene and protein expression ex vivo in whole lung
tissue derived from sugen5416/hypoxic rats. Gene expres-
sion of Cx43 remains unchanged (Fig. 6a); however, protein
expression of Cx43 was increased in whole lung tissue from
sugen5416/hypoxic rats (Fig. 6b and c). Interestingly,
sugen5416/hypoxic rats dosed with the ASK-1 inhibitor
GS-444217, which attenuated PH in these rats,17 did not
show an increase in Cx43 protein expression.
Discussion
To our knowledge, this is the first study to investigate the
role of Cx43 in rPAFs in response to hypoxia. The data
presented here show that in rPAFs, Cx43 protein expression
is increased by hypoxia and that Cx43 plays a role in
hypoxic-induced proliferation and migration as well as
hypoxic-induced phosphorylation of both p38 and ERK1/
2 MAPK. Cx43 protein expression is also upregulated in
whole lung tissue derived from sugen5416/hypoxic rats, an
effect dependent upon the ASK-1/MAPK pathway.
Interestingly, a previous study showed that Cx43 expres-
sion was increased in pulmonary arteries from patients with
chronic hypoxic PH and that mice heterozygous for Cx43
were protected against hypoxic-induced pulmonary vascular
remodelling.9 Thus, the data presented in this manuscript
build on the hypothesis that Cx43 may be a promising ther-
apeutic target for the treatment of PH associated with
chronic hypoxia.
In this study, it was confirmed that GJA1, which encodes
Cx43, is the predominantly expressed connexin gene in both
rPAFs and rPASMCs. This is similar to many other cell
types such as keratinocytes, bone cells and fibroblast skin
cells where GJA1 is the predominant connexin gene
expressed.25,26 Although mRNA expression of the majority
of connexins studied remained unaltered following 24 h
hypoxic exposure in both rPAFs and rPASMCs, GJA4,
which encodes Cx37, was downregulated in rPASMCs.
This is in line with other studies which found that GJA4
gene expression was reduced in the right ventricular tissue
of pulmonary artery banded mice27 and also in PAECs from
Fig. 3. Effects of Cx43 inhibition on hypoxia-induced proliferation of rPAFs and rPASMCs. In rPAFs, a significant increase in cell proliferation was
observed in hypoxic cells. Gap27 (a) and Cx43 siRNA (b) were both shown to decrease proliferation in hypoxic rPAFs. Hypoxia did not alter
rPASMC proliferation (c). Data are expressed as mean SEM, and analysis was carried out by two-way ANOVA with a Tukey post hoc test.
*p< 0.05, ***p< 0.001, ****p< 0.0001, n¼ 8–9.
rPAF: rat pulmonary artery fibroblasts; rPASMC: rat pulmonary artery smooth muscle cells; SFM: serum-free media.
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PAH patients.14 In the current study, hypoxia downregu-
lated protein expression of Cx37 and Cx40 in rPASMCs
and increased protein expression of Cx37 and Cx43 in
rPAFs. In PAH patients, a recent study showed that both
Cx37 and Cx40 mRNA and protein expression were
decreased in isolated PAECs and in lung endothelial
layers.28 The rat monocrotaline model also showed
decreased Cx40 gene and protein expression in both whole
lung and isolated PASMC,12 and the mouse hypoxic model
showed decreased Cx40 gene expression in the pulmonary
artery.8 The increased Cx43 protein expression observed in
the current study in response to hypoxia aligns with pre-
vious studies which have shown Cx43 expression to be
increased in pulmonary arteries from patients with chronic
hypoxic PH and also in pulmonary arteries from chronic
hypoxic rats as well as monocrotaline rats.9,28,29
Conversely, using a C57BL6 mouse model subjected to 14
days of hypoxia, we showed a decrease in Cx43 gene and
protein expression in the pulmonary artery,11 while another
study found a 21-day hypoxic exposure to have no effect on
CX43 gene expression in the CD1 mouse pulmonary artery.9
Thus, Cx43 may be differentially regulated by hypoxia
depending upon the strain/species as well as the duration
of hypoxic exposure. While we may expect a correlation
between changes in gene expression and changes in protein
expression, this correlation can be as low as 40% in
Fig. 4. Effects of Cx43 inhibition on hypoxic-induced migration of rPAFs and rPASMCs. A significant increase in migration was observed in rPAFs
in response to hypoxia. This hypoxia-mediated increase was prevented with the addition of Gap27 (a, upper panel) or Cx43 siRNA (b, central
panel). Hypoxia did not alter rPASMC migration which was also unaltered with the addition of Gap27 (c, lower panel). The column on the right
shows an example of the scratch assay, while quantitative data from 4 to 9 assays are shown in the column on the left. Images are 10
magnification. Data expressed as mean SEM, and analysis was carried out by two-way ANOVA with a Tukey post hoc test. **p< 0.01,
***p< 0.001.
rPAF: rat pulmonary artery fibroblasts; rPASMC: rat pulmonary artery smooth muscle cells; SFM: serum-free media.
8 | Connexin 43 and pulmonary arterial fibroblasts McNair et al.
eukaryotes. Post-transcriptional regulation and rates of pro-
duction and degradation of mRNA and protein molecules
play a role in variation between mRNA and protein abun-
dance.30 For example, in mammalian cells, the rate of pro-
duction of mRNA is generally much lower than that of
production of protein.31
Increased proliferation and migration of rPAFs in
response to hypoxia is well established and is thought to
be important in hypoxic-induced remodelling of the pul-
monary vasculature.2 We showed Gap27 or siRNA directed
against Cx43 to inhibit the hypoxic-induced proliferative
and hypoxic-induced migratory responses observed in
rPAFs, thus providing evidence that Cx43 plays a role in
these responses. As we did not determine expression of other
connexins in rPAFs in response to Gap27 or siRNA directed
against Cx43, we cannot rule out that other connexins may
also be involved in these responses. Until now, studies of
connexins in the vasculature have focused on endothelial
and smooth muscle cells, with little known about connexins
in vascular fibroblasts. However, the role of connexins in
migration has been studied in skin fibroblasts. Contrary to
our findings, Gap27 and siRNA directed against Cx43 have
been shown to increase the rates of migration in primary
juvenile human dermal fibroblasts.32–34 Interestingly, how-
ever, Gap27 did not affect migration in human neonatal or
adult dermal fibroblasts.34 These disparities could be due to
species variation or differences in cell types. In the current
study, proliferation of rPAFs was determined using an auto-
mated cell counter which gives living and dead cell concen-
trations; therefore, we could rule out Gap27 or Cx43 siRNA
causing cell death. Hypoxic-induced migration of rPAFs
was observed using low serum concentrations (0.1% FBS)
which were not sufficient to uncover the hypoxic-induced
proliferative response, therefore confirming that migration
was independent of proliferation. In line with our results,
connexins, and in particular Cx43, have been shown to play
Fig. 5. Effects of Gap27 on MAPK expression in rPAFs. Hypoxia increased phosphorylated p38 (a and b) and phosphorylated ERK1/2 (c–e)
expression in rPAFs, an effect prevented by Gap27. Western blot of phosphorylated p38 shown in (a) and quantitative analysis in (b). While
Western blot of phosphorylated ERK1/2 is shown in (c) and quantitative analysis of ERK1 in (d) and ERK2 in (e). Data expressed as mean SEM,
and analysis was carried out by two-way ANOVA with a Tukey post hoc test. Lanes 1 and 4 contain 0% serum, Lanes 2 and 5 contain 1% serum
and Lanes 3 and 6 contain 1% serumþ 300 mM of Gap27. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001, n¼ 4.
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a role in cancer cell migration and proliferation.35,36 In rat
hepatocellular carcinoma cells, silencing Cx43 with siRNA
resulted in a 30% decrease in cell migration, whereas in bone
cells, increases in Cx43 showed a three- to fourfold increase
in cell proliferation.37 In the current study, rPASMCs pro-
liferated in response to 1% FBS to a similar degree under
both normoxic and hypoxic conditions. While our finding
that rPASMCs do not proliferate in response to hypoxia is
in agreement with some previous studies,17,38 others have
shown hypoxic-induced proliferation of rPASMCs. You
et al. reported that rPASMCs proliferated when exposed
to hypoxic conditions of 3% O2 for 48 h (5% O2 for 24 h
was used in the current study). It is of interest that Jiang
et al. exposed rPASMCs to 3% O2 for 24, 48 and 72 h,
observing only a small increase in proliferation at 24 h,
with the largest increase in proliferation observed at
72 h.39,40 In the current study, rPASMC and rPAF prolif-
eration was assessed under identical experimental condi-
tions. It is of interest to note that the rPASMCs studied
are capable of proliferation as this was observed in response
to serum.
As expected, FBS-induced proliferation of rPASMCs and
our study found Gap27 to have no effect on this. Previous
studies have shown connexins to mediate systemic vascular
SMC proliferation and migration. MAPK phosphorylation
of Cx43 has been shown to be critical in PDGF-induced
proliferation of mouse aortic smooth muscle cells.16 In
saphenous vein SMCs, an over-expression of Cx43 caused
an increase in cellular proliferation and migration in
response to angiotensin II, whereas Cx43 siRNA inhibited
these effects.41 A possible explanation for the disparity
between these results and those of the current study could
be due to differences between the pulmonary and systemic
circulation.42 Different responses between the pulmonary
and systemic circulation have been well documented with
one example being chronic hypoxia resulting in increased
cell proliferation via p38 MAPK in PAFs but causing no
change in aortic fibroblasts or mesenteric fibroblasts.43
Having established that inhibition of Cx43 caused
changes in rPAF function, we wished to examine the signal-
ling mechanism involved in these changes. Previous research
has shown that the MAPK pathway, and in particular p38
MAPK, is key in hypoxic-induced proliferation and migra-
tion of rPAFs.44 It has also been shown that phosphoryla-
tion of ERK1/2 is increased by hypoxia in rPAFs.44 In the
current study, Gap27 inhibited phosphorylation of p38
MAPK and ERK1/2 in hypoxic rPAFs. This suggests that
the MAPK-mediated proliferation and migration which
occurs in rPAFs requires connexin-mediated signalling.
Evidence from the literature suggests reciprocal interactions
between these pathways rather than one pathway being
upstream of the other. For example, inhibition of Cx43
has been shown to lead to a decrease in phosphorylation
of ERK1/2 and decreased cellular proliferation, while phar-
macological inhibition of ERK1/2 reduced expression of
Cx43 in human umbilical vein endothelial cells.45 In addi-
tion, Cx43 has MAPK phosphorylation sites located on the
carboxyl tail and has previously been shown to augment p38
MAPK-mediated cell migration.15 MAPK phosphorylated
Cx43 has also been shown to interact with cyclin E in mouse
Fig. 6. Connexin 43 gene and protein expression in sugen5416/hypoxic lung tissue. Sugen5416/hypoxic rats showed no changes in GJA1 (Cx43)
gene expression compared to control rats. The ASK-1 inhibitor GS-444217 also had no effect on gene expression of GJA1, n¼ 5–7 (a). Increased
Cx43 protein expression was observed in sugen5416/hypoxic rats in comparison to control rats. This increase in Cx43 protein expression was
reversed in sugen5416/hypoxic rats treated with the ASK-1 inhibitor GS-444217 (n¼ 4), Western blot shown in (b) and quantitative analysis in
(c). Data expressed as mean SEM, and analysis was carried out by two-way ANOVA with a Tukey post hoc test. *p< 0.05.
Cx43: connexin 43.
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vascular SMCs, and this interaction is critical for vascular
SMC proliferation.16 p38MAPK/ERK signalling has been
shown to induce membrane Cx43 internalisation in osteo-
cyte-like MLO-Y4 cells.46 On the other hand, Cx43 depho-
sphorylation at serine 282 activates the p38 pathway in
cardiomyocytes,47 and opening of Cx43 hemichannels has
been shown to activate p38 MAPK in mouse cortical astro-
cytes.48 In future studies, it would be of interest to further
investigate the relationship between Cx43 and the MAPK
pathway in rPAFs.
ASK-1 is a member of the MAPK family that becomes
auto-phosphorylated in response to oxidative stress. Once
phosphorylated, ASK-1 activates other downstream mem-
bers of the MAPK pathway such as p38 MAPK and c-Jun
N-terminal kinase.49 ASK-1 inhibition decreases rPAF
migration and proliferation in response to 24 h hypoxia.17
In the sugen5416/hypoxic rat model of PH, inhibiting ASK-
1 decreased right ventricular pressure and vascular remodel-
ling in vivo.17 In vitro rPAFs derived from sugen5416/
hypoxic rats displayed increased proliferation, migration
and p38 MAPK expression; these effects were not present
in rPAFs derived from sugen5416/hypoxic rats dosed with
the ASK1 inhibitor, GS-444217.17 Using lung tissue from
these sugen5416/hypoxic rats, we investigated if the changes
seen in vivo and in vitro also coincided with an altered con-
nexin expression. We observed no changes in GJA1 (Cx43)
gene expression in lung tissue from sugen5416/hypoxic rats.
Cx43 protein expression was increased in the lung tissue
from these rats; however, this increased Cx43 protein
expression was not observed in the lung tissue of rats treated
with GS-444217. These observations provide further evi-
dence for interactions between the MAPK and Cx43 signal-
ling pathways.
Interestingly, the results in whole lung tissue display a
similar pattern to that observed in rPAFs, with hypoxia alter-
ing protein expression but not gene expression of Cx43. As
noted earlier, changes in gene and protein expression fre-
quently do not correlate.30 Previous studies have also found
a possible link between Cx43 and ASK-1. Interactions
between Cx43 and ASK-1 were identified via co-immunopre-
cipitation experiments in primary astrocytes,50 and an inter-
action between Cx43 and ASK1 is thought to mediate
apoptosis in human embryonic kidney cells.51
In conclusion, we have shown that in rPAFs, Cx43 has an
important role in mediating hypoxic-induced proliferation
and migration, via increased phosphorylation of p38 MAPK
and ERK1/2. We have also shown that Cx43 protein expres-
sion is increased in lung tissue from the sugen5416/hypoxic
model. Thus, the present study provides further evidence
that Cx43 is involved in aberrant cellular proliferation asso-
ciated with the remodelling of the pulmonary vasculature in
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